Salmonella septicemia in rheumatoid arthritis patients receiving anti–tumor necrosis factor therapy: Association with decreased interferon‐γ production and toll‐like receptor 4 expression
Open Access
- 2 July 2003
- journal article
- research article
- Published by Wiley in Arthritis & Rheumatism
- Vol. 48 (7) , 1853-1857
- https://doi.org/10.1002/art.11151
Abstract
Objective Patients treated with antibodies to tumor necrosis factor α (TNFα) have an increased susceptibility to intracellular infections. We describe 2 patients with rheumatoid arthritis (RA) who developed Salmonella septicemia during anti‐TNF treatment. The aim of this study was to identify the mechanisms involved in the increased susceptibility of anti‐TNF–treated patients to intracellular microorganisms. Methods We evaluated an additional 6 RA patients receiving anti‐TNF antibodies, 5 RA patients not receiving anti‐TNF therapy, and 6 age‐ and sex‐matched healthy volunteers. The in vitro production of cytokines (interleukin‐1β [IL‐1β], IL‐6, interferon‐γ [IFNγ], and IL‐10) upon bacterial stimulation of whole blood and the expression of Toll‐like receptor 4 (TLR‐4) on dendritic cells from RA patients treated with infliximab, RA patients not treated with infliximab, and healthy controls were compared. Results Stimulation with heat‐killed Salmonella typhimurium or Candida albicans led to a significantly decreased production of IFNγ, but not to a decreased production of IL‐10, IL‐β, or IL‐6, in anti‐TNF–treated RA patients compared with RA patients who were not receiving anti‐TNF antibodies and compared with healthy controls. TNF‐blocking treatment ex vivo significantly inhibited TLR‐4 expression on dendritic cells from RA patients and healthy controls. Conclusion Since recognition of microorganisms by TLR‐4 and activation of phagocytes by IFNγ are essential mechanisms for the defense against intracellular and fungal pathogens, we propose that this pathway is crucial for the increased susceptibility to these microorganisms in patients receiving anti‐TNF therapy.Keywords
This publication has 15 references indexed in Scilit:
- Human Toll‐Like Receptor 4 Mutations but Not CD14 Polymorphisms Are Associated with an Increased Risk of Gram‐Negative InfectionsThe Journal of Infectious Diseases, 2002
- Genetics, cytokines and human infectious disease: lessons from weakly pathogenic mycobacteria and salmonellaeNature Genetics, 2002
- The Role of Toll‐like Receptor (TLR) 2 and TLR4 in the Host Defense against Disseminated CandidiasisThe Journal of Infectious Diseases, 2002
- In Vivo Expression of Toll-Like Receptor 2 and 4 by Renal Epithelial Cells: IFN-γ and TNF-α Mediated Up-Regulation During InflammationThe Journal of Immunology, 2002
- Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor α–Neutralizing AgentNew England Journal of Medicine, 2001
- Invasive Pulmonary Aspergillosis Associated with Infliximab TherapyNew England Journal of Medicine, 2001
- Involvement of CD14 and Toll-Like Receptors in Activation of Human Monocytes byAspergillus fumigatusHyphaeInfection and Immunity, 2001
- Tumor necrosis factor-α is required in the protective immune response against mycobacterium tuberculosis in miceImmunity, 1995
- Recombinant Interferon- Enhances Resistance to Acute Disseminated Candida albicans Infection in MiceThe Journal of Infectious Diseases, 1993
- Role of T cells, TNFα and IFNγ in recall of immunity to oral challenge with virulent salmonellae in mice vaccinated with live attenuated aro− salmonella vaccinesMicrobial Pathogenesis, 1992